July 14, 2021
Fierce Pharma
Related News
-
April 28, 2026Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
-
April 14, 2026
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform
-
February 18, 2026
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors
